European Biopharmaceutical Review |
 |
|
|
|
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| Comparing methods of valuing biotech, Frédéric Desdouits and Catherine Pichereau of Bionest find that valuation remains as much an art as a science, in Net Profit |
|
|
| When selling out or buying into intellectual property, Hayley French at Novartis Pharma AG asserts that due diligence must not be underestimated. In Intellectual Property: Due Diligence for Biotech, she examines its potential to provide an investor, purchaser or licencee with detailed information that may affect the target’s pricing, along with other key elements of the transaction |
|
|
| The Rewards of Diligence sees Ben Rapinoja and Anne Korpi-Filppula of Borenius & Kemppinen explain the importance of legal due diligence, and discuss how to avoid key legal risks in the life science industry |
|
|
|
| As competition continues to grow within the pharmaceutical industry, companies that trade on an international scale will need to find increasingly novel ways to view their market. Gary Muddyman of Conversis advises that we should Think Global, Act Local |
|
|
| The life science industry is in a state of constant flux – largely as a result of the unrelenting need for innovation and the threat of competition. To truly prosper in this challenging environment, Richard Barratt and Natalie Kingston at Morgan Lewis note that outsourcing companies should strive to offer flexible services, in Thinking Outside the Box |
|
|
| Dr John Hall and Duncan Birne at AAI Pharma raise concerns as to the current modus operandi for outsourcing in the biopharma sector. Recognising that the past decade has seen the growth of a scientifically sophisticated biotech industry, they pose the question: Outsourcing for Biotechs: The Need for a New Model? |
|
|
| Crossing the Pond explores the mutual benefits of transatlantic venture capital collaboration. Hanns-Peter Wiese and Dr Stephen J McCormack of Global Life Science Ventures chart the progress of the European biotech companies playing catch up with the US |
|
|
|
| Dr Ole Jørgen Marvik and Dr Jutta Heix at HUNT Biosciences analyse the future development of biobanks and their impact on medical genomics, in Biobanking Potential |
|
|
| Around 2.9 million cases of cancer are diagnosed in Europe each year and this extensive disease burden results in over 700,000 annual deaths. In Anti-Tumour Agents: The Next Generation, Steve Dawber identifies current innovations and future developments in blood cancer-targeted pharmacotherapy, in search of significant prognostic improvements |
|
|
|
|
| Voula Kodoyianni at GWC Technologies, Inc and Richard Rouse at HTS Resources, LLC look at Tailor-Made Therapies – the rise of targeted, personalised therapeutics – and discover how unique genetic fingerprints can lead to more effective disease treatments |
|
|
| The past decade has witnessed a soaring increase in our knowledge of the human genome and the link between genes and disease. Henrik Ørum at Santaris Pharma reviews new developments in the field of antisense therapies and asks, Oligonucleotide Drugs – Within Sight of the Finish Line? |
|
|
|
| In Counteracting the Virus Threat, Dr Andy Bailey at ViruSure GmbH investigates current issues in the validation of biopharmaceuticals for virus clearance |
|
|
| Suzanne M Sensabaugh at MDS Pharma Services examines biomarkers within biopharmaceutical drug advancement programmes and finds that they are forces Driving Development |
|
|
| In Mass Spectrometry in Peptide Biomarker Discovery and Peptidomics, Rodion Demin at DIGILAB BioVisioN GmbH discusses the requirements of peptidomics technology related to mass spectrometry and the differences compared with proteomics in biomarker discovery |
|
|
| For investors, shareholders and executives alike, an abiding question is: how can a company speed time-to-market, lower costs and improve their success rate? John Avellanet at Cerulean Associates LLC recommends Quality By Design: Defining Your Preclinical Package |
|
|
|
| The Future of Liquid Chromatography sees Robert Plumb and Jeffrey R Mazzeo at Waters outline the crucial factors shaping the selection of a new liquid chromatography platform |
|
|
| Increased competition, shareholder influence and challenging targets are putting biopharmaceutical manufacturers under pressure. Eugène van Dijk at WCI Consulting Limited notes, in Quality Control Crosses into the Dead Zone, that whilst scaleability and productivity have become key drivers for selecting both cell lines and technology, when it comes to quality control these principles are not widely applied |
|
|
| Clemens Achmüller and Bernhard Auer at the Austrian Center of Biopharmaceutical Technology, Institute of Biochemistry, University of Innsbruck, Austria, investigate fusion protein technology for expression of therapeutic proteins and peptides in E coli, in The Protein Production Line |
|
|
|
| In A CEE of Opportunity, Bogdan Nietubyc of Hesperion Ltd explores factors influencing the increase in patient recruitment rates recently experienced by the CEE region and Russia |
|
|
| Nicola Watkinson at Invest Australia analyses Australia’s maturing biotech market, and finds that European companies are frequently considering Australia in the push to take drugs to market, in New Opportunities |
|
|
|
|
|
